Bowden C - Search Results

1

A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma.

Small EJ, Figlin R, Petrylak D, Vaughn DJ, Sartor O, Horak I, Pincus R, Kremer A, Bowden C. Small EJ, et al. Among authors: bowden c. Invest New Drugs. 2000 May;18(2):193-7. doi: 10.1023/a:1006386115312. Invest New Drugs. 2000. PMID: 10857997 Clinical Trial.

2

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH. Zujewski J, et al. Among authors: bowden c. J Clin Oncol. 2000 Feb;18(4):927-41. doi: 10.1200/JCO.2000.18.4.927. J Clin Oncol. 2000. PMID: 10673536 Clinical Trial.

3

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C. End DW, et al. Among authors: bowden c. Cancer Res. 2001 Jan 1;61(1):131-7. Cancer Res. 2001. PMID: 11196150

4

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.

Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Bitton RJ, et al. Among authors: bowden c. J Clin Oncol. 1995 Sep;13(9):2223-9. doi: 10.1200/JCO.1995.13.9.2223. J Clin Oncol. 1995. PMID: 7666080 Clinical Trial.

5

Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.

Lubet RA, Steele VE, DeCoster R, Bowden C, You M, Juliana MM, Eto I, Kelloff GJ, Grubbs CJ. Lubet RA, et al. Among authors: bowden c. Carcinogenesis. 1998 Aug;19(8):1345-51. doi: 10.1093/carcin/19.8.1345. Carcinogenesis. 1998. PMID: 9744527

6

Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.

Bowden CR, Voina SJ, Woestenborghs R, De Coster R, Heykants J. Bowden CR, et al. J Pharmacol Exp Ther. 1992 Aug;262(2):699-706. J Pharmacol Exp Ther. 1992. PMID: 1380082

7

Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown.

De Coster R, Wouters W, Van Ginckel R, End D, Krekels M, Coene MC, Bowden C. De Coster R, et al. Among authors: bowden c. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):197-201. doi: 10.1016/0960-0760(92)90208-z. J Steroid Biochem Mol Biol. 1992. PMID: 1525060 Review.

8

Effect of the fatty acid oxidation inhibitor methyl palmoxirate (methyl 2-tetradecylglycidate) on recovery from insulin-induced hypoglycemia in diabetic dogs.

Tuman RW, Bowden CR, Inman M, Altszuler N, Tutwiler GF. Tuman RW, et al. Among authors: bowden cr. J Pharmacol Exp Ther. 1989 Sep;250(3):836-41. J Pharmacol Exp Ther. 1989. PMID: 2674419

9

New non-steroidal aromatase inhibitors: focus on R76713.

De Coster R, Wouters W, Bowden CR, Vanden Bossche H, Bruynseels J, Tuman RW, Van Ginckel R, Snoeck E, Van Peer A, Janssen PA. De Coster R, et al. Among authors: bowden cr. J Steroid Biochem Mol Biol. 1990 Nov 20;37(3):335-41. doi: 10.1016/0960-0760(90)90482-z. J Steroid Biochem Mol Biol. 1990. PMID: 2257238 Review.

10

Pharmacology of vorozole.

Wouters W, Van Ginckel R, Krekels M, Bowden C, De Coster R. Wouters W, et al. Among authors: bowden c. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):617-21. doi: 10.1016/0960-0760(93)90268-2. J Steroid Biochem Mol Biol. 1993. PMID: 8386540

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

590 results

Search Page